• English
  • French
logo logo
  • English
  • French
  • About Us
  • Operations
  • Our Products
  • Programs
  • Contact
  • About Us
  • Operations
  • Our Products
  • Programs
  • Contact

Category: NATCO Global

  • Home
  • NATCO Global

Category: NATCO Global

January 6, 2022 natcopharma-wpdmn No Comments

NATCO completes acquisition of Dash Pharmaceuticals LLC

Read more >

Read More
December 6, 2021 natcopharma-wpdmn No Comments

NATCO receives approval for a drug for the treatment of Covid-19 in India

Read more >

Read More
December 6, 2021 natcopharma-wpdmn No Comments

NATCO proposes to acquire Dash Pharmaceuticals LLC

Read more >

Read More
November 6, 2021 natcopharma-wpdmn No Comments

NATCO launches Tipanat tablets in India, for the treatment of advanced colorectal and gastric cancer

Read more >

Read More
October 6, 2021 natcopharma-wpdmn No Comments

NATCO announces launch of its 10mg strength for Everolimus Tablets (generic for Afinitor®) in the US market

Read more >

Read More
August 4, 2021 natcopharma-wpdmn No Comments

NATCO transfers Lenalidomide ANDA to Arrow

Read more >

Read More
June 14, 2021 natcopharma-wpdmn No Comments

NATCO receives approval for Carfilzomib Vials ANDA (generic for KYPROLIS® ) in the US market

Read more >

Read More
May 26, 2021 natcopharma-wpdmn No Comments

NATCO receives tentative approval for Ibrutinib tablets (generic for IMBRUVICA®) ANDA in the US market

Read more >

Read More
May 22, 2021 natcopharma-wpdmn No Comments

NATCO receives USFDA approval for Lenalidomide Capsules

Read more >

Read More
May 21, 2021 natcopharma-wpdmn No Comments

NATCO starts Phase-III Clinical Trial of Molnupiravir capsules for Covid-19 treatment

Read more >

Read More
May 17, 2021 natcopharma-wpdmn No Comments

NATCO signs Voluntary Licensing Agreement with Lilly for Baricitinib for Covid-19 in India

Read more >

Read More
May 3, 2021 natcopharma-wpdmn No Comments

NATCO receives Emergency Use approval for Baricitinib tablets for Covid-19 treatment

Read more >

Read More
April 26, 2021 natcopharma-wpdmn No Comments

NATCO seeks Emergency approval of Molnupiravir capsules for Covid-19 treatment

Read more >

Read More
March 26, 2021 natcopharma-wpdmn No Comments

NATCO receives final approval for Everolimus tablets (generic for Afinitor® ) for the US market

Read more >

Read More
February 26, 2021 natcopharma-wpdmn No Comments

NATCO launches Brivaracetam tablets, in India, for treatment of epilepsy

Read more >

Read More
January 1, 2021 natcopharma-wpdmn No Comments

NATCO receives final approval for Everolimus tablets (generic for ZORTRESS9) in the US market

Read more >

Read More
NATCO PHARMA (CANADA) INC.

2000 Argentia Road, Plaza 1, Suite 200
Mississauga, Ontario L5N 1P7
Tel: (905) 997-3353 / (905) 593-1566
Fax: (905) 997-3354
Toll Free: 1 (800) 296-9329

HELPFUL LINKS
  • Contact Us
  • Privacy Policy
FOLLOW US

LinkedIn

NATCO WORLDWIDE

Natco Pharma Limited

Copyright © Natco Pharma (Canada) Inc., 2023. All rights reserved.